Most Read Articles
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Audrey Abella, 21 Sep 2020
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.

Pregabalin as monotherapy enough to manage fibromyalgia

26 Sep 2020

Pregabalin, used either alone or in combination with milnacipran, is effective in the treatment of patients with fibromyalgia, and combined therapy does not confer added benefits compared with monotherapy, according to a study.

The study randomized 58 female fibromyalgia patients to receive pregabalin 150 mg twice daily alone (n=29) or with milnacipran 50 mg twice daily (n=29) for 3 months. The median disease duration was 2 years, with an average tender point count of 14.

Patients in the combination arm had a numerically higher visual analogue scale (VAS) and fibromyalgia impact questionnaire (FIQ) scores, with 22 (84.6 percent) of them having severe pain (VAS ≥70) as compared with 15 (65.2 percent) in the monotherapy group. Pain was significantly correlated with disease impact at baseline in both groups.

The dropout rate was 20.7 with monotherapy and 10.3 percent with combination. At the follow‐up assessment, patients in both groups showed a statistically significant improvement in VAS and FIQ scores (p<0.001).

More patients on combination than on monotherapy achieved significant improvement in pain, disease impact, and sleep pattern. However, the difference was not clinically meaningful.

In light of the results, the researchers acknowledged that a population-based, multicentric study may reveal more significant findings. They suggested that future studies consider adding a placebo control and milnacipran comparator groups with blinding to obtain better data.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Audrey Abella, 21 Sep 2020
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.